Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 5Phase NA 3Phase 3 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Breast Neoplasms 250Carcinoma, Non-Small-Cell Lung 226Prostatic Neoplasms 118Neoplasms 106Multiple Myeloma 91Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 67Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 48Melanoma 47Carcinoma, Renal Cell 45Leukemia, Lymphocytic, Chronic, B-Cell 44Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Recurrence 41Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Nasopharyngeal Carcinoma 34Lymphoma, Follicular 34Head and Neck Neoplasms 34Pancreatic Neoplasms 32Rectal Neoplasms 31Lymphoma, Large B-Cell, Diffuse 30Endometrial Neoplasms 29

Interventions

Doxorubicin 2pembrolizumab 1olaratumab 1X-Rays 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Histiocytoma, Malignant Fibrous × 1 year × Clear all
NCT06422806 2026-05-29

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

National Cancer Institute (NCI)

Phase 3 Recruiting
365 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT02451943 2025-07-15

ANNOUNCE

Eli Lilly and Company

Phase 3 Completed
509 enrolled 23 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡